Clinical Research Directory
Browse clinical research sites, groups, and studies.
Muscle Impact of Treating Osteoporosis
Sponsor: Nami Safai Haeri
Summary
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity). There is strong evidence of overlap between the pathophysiology of osteoporosis and sarcopenia (muscle-bone crosstalk). This research plan will further explore the relationship between bone and muscle, and provide new information about effect of osteoporosis medications on muscle health in older adults who are under treatment for osteoporosis.
Official title: The Impact of Osteoporosis Medications on Muscle Health in Older Adults
Key Details
Gender
FEMALE
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2023-02-14
Completion Date
2026-09-05
Last Updated
2026-01-12
Healthy Volunteers
No
Conditions
Interventions
Denosumab
Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.
Zoledronic Acid
Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
Denosumab Placebo
Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.
Zoledronic Acid Placebo
Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
Locations (1)
University of Pittsburgh
Pittsburgh, Pennsylvania, United States